BrightSpring Health Services, Inc. Tangible Equity Unit · BTSGU · FY2026 Q3 · Calendar Q4 2026
BrightSpring Q3: Pharmacy Growth Offsets IRA Pressure
BrightSpring’s Q3 analysis supports a constructive operating trajectory: specialty pharmacy, infusion, home health, and acquisition contributions are driving growth, but IRA pressure and execution around LDD expansion remain important offsets.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about BTSGU FY2026 Q3
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The supplied Q3 analysis highlights double-digit revenue and EBITDA growth, a $50 million expected Q4 IRA headwind, on-track Amedisys/LHC integration, lower leverage, and continued investment in AI, technology, and acquisitions.
Guidance delta
Management reaffirmed 2026 guidance and signaled 15–20% organic adjusted EBITDA growth in 2027.
Key takeaways
- Specialty and infusion script growth, plus 19 branded LDD launches year to date, remained the main growth engine.
- Home health census growth and the Amedisys/LHC acquisition supported Provider Services; integration is on track.
- The IRA is expected to reduce home and community pharmacy revenue by about $50 million in Q4, though underlying organic growth remains solid.
Management priorities
- Continue branded LDD launches and expand specialty and infusion services.
- Scale chronic infusion, IG Connect, and virtual primary care offerings.
- Deepen AI and technology deployment while pursuing strategic acquisitions.
Follow BTSGU with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationBrightSpring Health Services, Inc. is a U.S.-based healthcare organization that provides a comprehensive suite of services directly to individuals in their homes and local communities. The company's primary focus is on delivering pharmacy and direct patient care services, encompassing both clinical treatment and supportive assistance. These services are specifically tailored for populations covered by Medicare, Medicaid, and private insurance. Care is administered by a network of clinical providers and pharmacists. Established in 1974, the firm is headquartered in Louisville, Kentucky, and adopted its current name, BrightSpring Health Services, Inc., in May 2021, having previously been known as Phoenix Parent Holdings Inc.
Healthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +12.3% | Regeneron: Core Brands Grow as Pipeline Milestones Advance |
| ILMN Illumina, Inc. | FY2026 Q3 · Calendar Q4 2026 | +19.1% | -16.8% | Illumina raises FY2026 outlook as clinical sequencing demand holds up |
| DVA DaVita Inc. | FY2026 Q3 · Calendar Q4 2026 | +7.0% | -6.8% | DaVita’s expanded HD rollout and IKC progress support a narrowed outlook |
| SYK Stryker Corporation | FY2026 Q3 · Calendar Q4 2026 | -0.8% | -5.0% | Stryker cuts guidance as hip and knee demand slows |
| DXCM DexCom, Inc. | FY2026 Q3 · Calendar Q4 2026 | +8.1% | +5.6% | Dexcom raises 2026 outlook as G7 15-Day adoption expands |
| ALNY Alnylam Pharmaceuticals, Inc. | FY2026 Q3 · Calendar Q4 2026 | +879.5% | -25.1% | Alnylam Q3: AMVUTTRA growth meets reimbursement uncertainty |
Latest beats and misses
Who reports nextBeat on EPS
- MTZFY2026 Q3 · October 29, 2026+0.3% EPS+0.8% move
- ERIEFY2026 Q3 · October 29, 2026+2.1% EPS+5.3% move
- IRFY2026 Q3 · October 29, 2026+18.5% EPS+0.2% move
- VLTOFY2026 Q3 · October 29, 2026+8.3% EPS+9.8% move
- MSTRFY2026 Q3 · October 29, 2026+121.6% EPS-6.3% move
- EIXFY2026 Q3 · October 29, 2026+3.3% EPS-0.2% move
Missed on EPS
- AMZNFY2026 Q3 · October 29, 2026-4.1% EPS-1.6% move
- SYKFY2026 Q3 · October 29, 2026-0.8% EPS-5.0% move
- DLR-PJFY2026 Q3 · October 29, 2026-8.4% EPS— move
- DLRFY2026 Q3 · October 29, 2026-8.4% EPS-3.0% move
- EGFY2026 Q3 · October 28, 2026-18.8% EPS+3.5% move
- MKLFY2026 Q3 · October 28, 2026-2.3% EPS+1.2% move
Get the BTSGU recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-10-30T15:10:40.644639+00:00
- FN2 earnings calendar · 2026-10-30T01:23:13.979536+00:00
- Polygon adjusted daily market bars · 2026-10-30T17:00:44.791956+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-30. For educational purposes only; not investment advice.